Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. The stock will provide you with a reasonable dividend income. Imprimis Pharmaceuticals, Inc. is not very popular among insiders. Imprimis Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It f...

News